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This study examined the effects of aliskiren (Ali) (direct renin inhibitor) on serum cardiac enzymes (LDH and CK-MB),
electrocardiography (ECG) changes, myocardial oxidative stress markers (MDA, CAT, and GSH) and the expression of
Bcl2, HO-1, and Nrf2 genes in isoproterenol (ISO)-induced myocardial infarction (MI). A total of 40 male albino rats
were allocated into four groups, (1) normal control (NC) group, (2) Ali group (rats received Ali at 10 mg/kg/day p.o. for
5 days), (3) ISO group (rats received ISO 150 mg/kg i.p. for two consecutive days at 24 h intervals), and (4) Ali+ ISO
group (rats received ISO+Ali at 10 mg/kg/day p.o. for 5 days from the 2nd dose of ISO). ISO group showed signiﬁcant
rise in serum cardiac enzymes (CK-MB and LDH), myocardial damage scores, myocardial MDA, HO-1, myocardial
Nrf2 expression with signiﬁcant reduction in myocardial antioxidants (CAT and GSH), and Bcl2 expression compared
to the normal group (p< 0.05). ECG showed ST segment elevation, prolonged QT interval and QRS complex, and
increased heart rate in ISO group. Co-administration of Ali and ISO caused signiﬁcant increase in cardiac enzymes and
morphology with increase in MDA, serum K, and creatinine with signiﬁcant decrease in Bcl2, HO-1, and Nrf2 without
signiﬁcant changes in ECG parameters compared to ISO group. We concluded that low dose of Ali seems to exacerbate
the myocardial injury in ISO-MI, which might be due to the enhanced oxidative stress and apoptosis.
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Introduction
World Health Organization (WHO) considers ischemic heart disease (IHD) as the main cause
of morbidity and mortality in the world, which will be the major cause of death by the year
2020 (38). Myocardial infarction (MI), a type of IHD, is caused by imbalance between
myocardial O2 supply and the demand that can be assessed by electrocardiography (ECG)
(26, 48). Experimental MI can be induced by ligation of coronary arteries (ischemic MI) or by
administration of β-adrenoceptor agonists, such as isoproterenol (ISO). ISO-induced MI is a
well-established MI animal model that possesses the same pathophysiological mechanisms
and morphological changes of human MI (14). Mechanisms underlying myocardial damage
and cardiac arrhythmias in ISO-induced MI involve reactive oxygen species (ROS) and
inﬂammatory cytokines production (59, 62). Recently, experimental studies have demon-
strated a role for transcription factor Nuclear factor erythroid 2-related factor 2 (Nrf2), heme
oxygenase-1 (HO-1), and apoptotic protein [such as B-cell/lymphoma 2 (Bcl2), Bax, and
caspases-3 and -9] in ischemic and ISO-induced MI (24, 35, 50).
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Renin–angiotensin system (RAS) plays an important role in the pathogenesis of many
clinical conditions of the cardiovascular system, such as atherosclerosis, hypertension, MI,
and heart failure (25). The RAS can be blocked at the levels of angiotensin (Ang)-converting
enzyme (ACE) and Ang receptor (AR) and at the point of activation (direct renin inhibitors,
DRI) (11). Aliskiren (Ali) is a non-peptide DRI that blocks the interaction between renin and
angiotensinogen and prevents its cleavage to Ang I (55), leading to a decrease in all
downstream components of the renin-angiotensin-aldosterone system (18). The role of RAS
in the development of ischemic and ISO-induced heart failure still remains uncertain.
Previous studies have demonstrated the beneﬁts of the long-term use of RAS inhibitors
including Ali in protection of myocardium after ischemic and ISO-induced injuries
(21, 27, 44, 47, 65, 66). Also, Leenen et al. (33) demonstrated that the activity of circulatory
RAS blunts the hypotensive effects of ISO-induced heart failure and treatment with ACEi and
angiotensin receptor blockers (ARBs) did not prevent the ISO-induced cardiac hypertrophy.
ARBs also enhanced the increase in myocardial collagen contact. Moreover, Guo et al. (19)
demonstrated that ARBs failed to demonstrate any beneﬁcial effect on ISO-induced
myocardial hypertrophy and interstitial ﬁbrosis. Thus, the effects of direct inhibition of
RAS in early ISO-induced MI need more clariﬁcation. Therefore, this study was designed to
investigate the effects of direct blockade of RAS using Ali on ECG changes, oxidative stress,
and expression of Nrf2/HO-1 pathway and apoptotic markers in a rat model of acute ISO-MI.
Materials and Methods
Experimental animals
A total of 40 adult male Sprague Dawley rats aged 3–4 months and weighing between 150
and 180 g were maintained at room temperature at Nile Center for Experimental Research and
had free access to food (standard pellet diet) and tap water ad libitum. This study was carried
out according to the guidelines of experimental lab animal care and ethics and was approved
by our local committee of ethics (approval no. R/16.12.87).
Drugs and chemicals
We purchased Tekturna tablets (Ali; 150 mg tablets) from Novartis, America, and ISO
hydrochloride from Sigma Chemical Co. (St. Louis, MO, USA).
Experimental model of ISO-induced MI
Animal model of ISO-induced MI was induced by i.p. administration of ISO (150 mg/kg
body weight; Sigma Chemical Co.) for two alternate days with 24-h intervals (52).
Experimental design
We randomly allocated rats into four groups as follows:
1. Normal control (NC) group (n = 8): normal rats received 0.5-ml saline i.p. every
alternate day for two alternate days and 0.5-ml saline p.o. every day for 5 days.
2. Ali group (n= 8): animals received Ali (10 mg/kg; (Rasilez tablets, Novartis Euro-
pharm Ltd. Co., UK; aliskiren 150 mg) p.o. for 5 days.
3. ISO + MI group (n= 12): animals received ISO only.
4. (Ali + ISO) group (n= 12): animals received ISO and Ali (10 mg/kg, orally for 2 days
before the 1st dose of ISO).
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Measurement of systolic BP and heart rate (HR)
Systolic BP and HR of animals were measured at basal (before ISO injection), and at Days 3
and 5 after the injection of ISO by a noninvasive rat tail BP monitor (ML 125 NIBP, AD
Instruments, Australia) at the Medical Physiology Department, Mansoura Faculty of Medi-
cine. The average of at least three measurements of BP was taken at each occasion.
ECG recording
In all rats, ECG recording was performed under light ether anesthesia at Day 0 (basal) and at
Days 3 and 5 after induction of MI using MP36 Biopac data acquisition Student Lab System
(software BSL 3.7.5, Medical Physiology Department, Mansoura Faculty of Medicine,
Egypt). Lead II was recorded and the following ECG variables were measured: HR, QT
intervals, QRS complex, and ST segment.
Blood sample collection and harvesting of the heart
We collected blood samples from the ophthalmic venous plexus of the rats by ﬁne-walled
Pasteur pipette under light halothane anesthesia. The collected blood was centrifuged and
serum was stored at −20 °C until the time of assay of cardiac enzymes [lactate dehydrogenase
(LDH) and creatine kinase-muscle/brain (CK-MB)]. In addition, at the end of the experiment,
rats were sacriﬁced by high dose of Na+ thiopental (120 mg/kg), then we opened the thorax
and the heart was rapidly excised. The excised heart was washed in ice–cold isotonic saline
and dissected into two parts; one part was stored in liquid nitrogen (−170 °C) for PCR assay
and biochemical analysis of oxidative stress markers, whereas the other part of the heart was
stored in formalin (10%) for histopathological examination.
Measurement of cardiac enzymes (CK-MB and LDH) and plasma renin activity (PRA)
We measured the serum cardiac enzymes (LDH and CK-MB) with commercially available
kits, according to the manufacturer’s instructions (Bayer Diagnostics Ltd., Baroda, India and
bioMérieux Diagnostics, Milan, Italy, respectively). PRA was determined by ELISA kit (cat
no.: CAN-RA-4600) according to the manufacturer’s instructions using Segma 690 micro-
plate reader and the results were expressed as nanograms of Ang I/ml/h.
Estimation of oxidative stress markers [malondialdehyde (MDA), catalase (CAT), and
glutathione (GSH)]
We homogenized a small part of cardiac tissue (~0.15 g) in cold phosphate buffer saline (pH
7.4, 50 mM), then aliquoted into different ependorffs and stored at −20 °C. We assessed the
concentration of MDA and reduced GSH and CAT activity in heart homogenates by
colorimetric kits (Bio-Diagnostics, Giza, Egypt) according to the manufacturer’s instructions.
Detection of mRNA of Nrf2, Bcl2, and HO-1 by RT-PCR in cardiac tissues
All procedures of RNA extraction and cDNA synthesis were done according to techniques
previously described (23). Primers of the investigated genes were as follows: Bcl2,
forward: atcgctctgtggatgactgagtac, reverse: agagacagccaggagaaacaac; glyceraldehyde
3-phosphate dehydrogenase, forward: ccagggctgccttctcttgt, reverse: ctgtgccgttgaacttgccg;
HO-1, forward: tcaccttcccgagcatcgac, reverse: tcaccctgtgcttgacctcg; Nrf2 (erythroid-
derived 2)-like 2 (Nrf2), forward: catttgtagatgaccatgagtcgc, reverse: gctccatgtcctgctgtatgc.
About 10 μl of PCR product was loaded on 2% agarose gel with ethidium bromide staining
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and the product was visualized on ultraviolet transilluminator and PCR products were
semi-quantiﬁed by a gel documentation system (BioDocAnalyze, Nile Center for Experi-
mental Research, Mansoura, Egypt).
Histopathological examination
The formalin-ﬁxed cardiac tissues were processed into parafﬁn blocks and hemotoxylin and
eosin staining was done. Cardiac tissues were examined for interstitial edema, inﬂammatory
cells, and necrosis of myocardial cells. Brieﬂy, the ﬁndings were graded as no changes;+mild
(focal myocyte damage or small multifocal degeneration with slight degree of inﬂammatory
process); ++moderate (extensive myoﬁbrillar degeneration and/or diffuse inﬂammatory
process); and +++marked (necrosis with diffuse inﬂammatory process). According to the
observed histopathological changes in myocardial tissue, all rats were divided into three
groups: group A (no histopathological change), group B (mild histopathological change), and
group C (moderate and/or severe histopathological changes) (41).
Statistical analysis
Wemeasured the statistical signiﬁcance among groups by using one-way analysis of variance
test followed by Tukey’s post hoc test. SPSS version 20 was used to perform the statistical
analysis. p value of <0.05 was considered signiﬁcant.
Results
Results of animal survival in different groups
Kaplan curve showed that the survival rate was lesser in the Ali+ ISO group compared to the
NC, Ali, and ISO groups. By the end of the experiment, 8 of 8 rats survived in the NC group,
10 of 12 rats in the Ali group, 9 of 12 rats in the ISO group, and 6 of 12 rats in the Ali+ ISO
group (Fig. 1).
Effects of Ali on biochemical markers (serum LDH, CK-MB, creatinine, K+, and PRA)
in ISO-MI
Basal values of serum cardiac enzymes (LDH and CK-MB), serum K and creatinine and PRA
showed no statistical signiﬁcance among all groups (NC, Ali, ISO, and Ali + ISO groups). In
addition, compared to the NC group, the Ali group showed no statistically signiﬁcant
difference in these parameters at Days 3 and 5. At Days 3 and 5, the levels of LDH and
CK-MB and PRA showed signiﬁcant increase in the ISO and the Ali+ ISO groups compared
to the NC and the Ali groups (p≤ 0.01). Furthermore, serum levels of CK-MB and LDH
showed signiﬁcant increase in the Ali + ISO group at Days 3 and 5 compared to the ISO and
the Ali groups (p< 0.05), whereas PRA activity did not show any statistical signiﬁcant
difference between the ISO and the Ali + ISO groups. Regarding serum K and creatinine,
they were signiﬁcantly higher in the Ali+ ISO group compared to the NC, Ali, and ISO
groups at Days 3 and 5 (p< 0.05) (Table I).
Effect of Ali on body weight, heart weight/body weight, systolic BP, HR, and ECG variables
(QT interval, QRS complex, T wave, and ST segment) in ISO-MI
At basal levels, body weight, heart weight/body weight, arterial blood pressure (ABP), HR,
and ECG variables (QT interval, QRS complex, and ST segment) showed no statistically
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signiﬁcant difference among all studied groups (NC, ISO, and Ali groups). There is no
statistically signiﬁcant difference between the Ali and the NC groups in all these parameters.
Body weight was signiﬁcantly lower and the heart weight/body weight ratio was higher in the
ISO and the Ali+ ISO groups compared to the NC and the Ali groups (p< 0.05) with no
statistically signiﬁcant difference between the ISO and the Ali + ISO groups at Days 3 and 5.
Systolic BP was signiﬁcantly lower in the ISO and the Ali+ ISO groups compared to the NC
group (p< 0.05) with no statistically signiﬁcant difference between the ISO and the
Ali + ISO groups at Day 3, but it was signiﬁcantly lower in the Ali+ ISO group than in
the ISO at Day 5 (p< 0.05). HR and ST segment, QT interval, and QRS complex were
signiﬁcantly higher in the ISO and the Ali + ISO groups than in the NC and the Ali groups at
Days 3 and 5 (p< 0.01). QT interval, QRS complex, and ST segment showed no statistically
signiﬁcant difference between the ISO and the Ali+ ISO groups (Table II). Figure 2a–d
shows representative samples of ECG recordings at Day 0 from the NC, Ali, ISO, and
Ali + ISO groups, respectively and Fig. 2e–h shows representative samples at Day 5 from the
NC, Ali, ISO, and Ali+ ISO groups, respectively. ECG tracings showed increased T-wave
amplitude in the ISO+Ali group (Fig. 2h).
Effect Ali on myocardial oxidative stress markers (MDA, CAT, and GSH) in ISO-MI
Compared to the NC and the Ali groups, MDA concentration was signiﬁcantly higher in the
ISO and the Ali+ ISO groups, while CAT activity and GSH concentration were signiﬁcantly
lower in the ISO and the Ali + ISO groups (p< 0.01). On the other hand, the Ali + ISO group
showed a signiﬁcant increase in MDA with signiﬁcant decrease in GSH and CAT activity
compared to the ISO-induced MI group (p< 0.01; Fig. 3a–c).
Fig. 1. Kaplan–Meier survival curves of the NC, Ali, ISO, and Ali+ ISO groups
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Effect of Ali on myocardial expression of HO-1, Bcl2, and Nrf2 in ISO-MI
Expression of mRNA of HO-1 in myocardium did not show statistically signiﬁcant difference
between the NC and the Ali groups, but it showed a signiﬁcant increase in the ISO group
(a) (b)
(c) (d)
(e) (f)
(g) (h)
Fig. 2. Normal ECG waves and intervals in the NC group (a), the Ali group (b), the ISO group (c), and the Ali+ ISO
group (d) at Day 0 and in the NC group (e) at Day 5, tall peaked T-wave in the Ali group (f), elevated ST segment in
the ISO group (g), and tall peaked T wave and elevated ST segment in the Ali+ ISO group (h) at Day 5
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compared to the NC and the Ali groups, and a signiﬁcant decrease in the Ali+ ISO group
compared to the NC and the ISO groups (p< 0.01). On the other hand, Bcl2 expression in the
myocardium showed a signiﬁcant decrease in the ISO and the Ali + ISO groups compared to
the NC and the Ali groups, and a signiﬁcant decrease in the Ali+ ISO group compared to the
ISO groups (p< 0.01). Accordingly, Nrf2 expression in the myocardium showed a signiﬁcant
increase in the ISO group compared to the NC and the Ali groups, and a signiﬁcant decrease
in the Ali + ISO group compared to the NC and the ISO groups (p< 0.01; Fig. 4a–c).
Effect of Ali on myocardial morphology in ISO-MI
The score of myocardial damage in all rats from the NC group and most of rats in the Ali
group was A, while most rats in the ISO and the Ali + ISO groups obtained score C
(Table III). Figure 5a–d shows normal structure of myocardium from the NC group (Fig. 5a
and b) and the Ali group (Fig. 5c and d) and Fig. 5e–g shows an infarcted zone with
interstitial edema with massive inﬂammatory cells inﬁltration (ISO group) and myoﬁbrillary
degeneration. The hearts obtained from the Ali+ ISO-treated rats showed massive myocar-
dial necrosis with interstitial hemorrhage and neutrophil cell inﬁltration (Fig. 5h–j).
Discussion
The following are the main ﬁndings of this study. (1) ISO administration at a dose of 150 mg
caused signiﬁcant deterioration in ECG parameters, elevation in oxidative stress, and
apoptotic markers, and upregulation of HO-1 and Nrf2 expression. (2) Direct inhibition of
RAS by low dose of Ali before ISO induction caused more signiﬁcant deterioration in the
Fig. 3. Markers of oxidative stress in myocardial muscles. Concentrations of MDA (nmol/g heart tissues) (a), GSH
(mg/g heart tissues) (b), and catalase activity (U/g heart tissues) (c) at Day 5. The symbol “*” denotes signiﬁcant
versus NC group, “#” denotes signiﬁcant versus Ali group, and “$” denotes signiﬁcant versus ISO group
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Fig. 4. The expression and RT-PCR products of Nrf2 (a), HO-1 (b), and Bcl2 (c) in myocardial muscles at Day 5. The
symbol “*” denotes signiﬁcant versus NC group, “#” denotes signiﬁcant versus Ali group, and “$” denotes
signiﬁcant versus ISO group
Table III. Number of rats in each histopathological damage score of myocardium in different groups
Group A Group B Group C
NC group 8 – –
Ali group 8 2 –
ISO group – 4 5
Ali+ ISO group – 2 4
NC: normal control; ISO: isoproterenol; Ali: aliskiren; Group A: no histopathological changes; Group B: mild
histopathological changes; Group C: moderate and/or severe histopathological changes
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studied parameters, whereas inhibition of RAS in normal rats did not cause any signiﬁcant
change in the studied parameters. In this study, we conﬁrmed previous ﬁndings that showed a
signiﬁcant rise in serum levels of LDH and CK-MB in the ISO group, which was expected as
a consequence of destruction of myocardial cell membranes by ISO (12, 41, 46). In
Fig. 5. Specimens of myocardium from the NC group showing normal architecture of rat myocardium at 200× (a) and
400× (b), from the Ali group showing normal architecture of rat myocardium at 200× (c) and 400× (d), from the ISO
group, area of infarction with interstitial edema with marked neutrophil inﬁltration at 400× (e–g), and from the
Ali+ ISO group, area of infarction with marked interstitial edema with acute extensive myoﬁbrillary degeneration
and hemorrhage (h), severe interstitial edema with marked neutrophil inﬁltration and moderate myoﬁbrillary
degeneration (i), and interstitial edema with interstitial hemorrhage (j) (H&E, 400×)
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consistence with functional abnormalities of cardiac functions, histopathological examination
of cardiac tissues obtained from the ISO-MI group showed the characteristic ﬁndings of MI.
These ﬁndings are similar to those reported by Dhalla et al. (12) and Metias et al. (41).
Recently, Khan et al. (30) reported that administration of ISO (85 mg/kg) in two doses with
24-h intervals in rats caused a signiﬁcant increase in markers of cardiac injury (LDH and
CK-MB) with signiﬁcant reduction in ABP, maximum rate of development of left ventricular
(LV) pressure, and increase in LV end diastolic pressure.
Unfortunately, direct inhibition of RAS by low dose (10 mg/kg) of Ali before ISO-MI
caused more signiﬁcant deteriorations in the serum levels of cardiac enzymes (LDH and
CK-MB) and myocardial histopathology compared to the ISO group, suggesting a negative role
for RAS inhibition in early stages of ISO-MI. In agreement with these ﬁndings, Guo et al. (19)
demonstrated that the inhibition of RAS with ARBs (Telm 10 mg/kg) had no effect
on ISO-induced myocardial hypertrophy and interstitial ﬁbrosis. Also, Leenen et al. (33)
demonstrated that the activity of circulatory RAS blunts the hypotensive effects of ISO-induced
heart failure and treatment with ACEi (quinapril) and ARBs (losartan) did not prevent the
ISO-induced cardiac hypertrophy as well as ARBs enhanced the increase in myocardial
collagen contact. Also, Huang et al. (22) and Jia et al. (27) reported that Ali and other RAS
inhibitors deteriorated the LV function after MI in animals and Solomon et al. (54) demon-
strated that the use of RAS blockers did not attenuate the LV function signiﬁcantly in high-risk
patients at 36 weeks after MI. Also, Jia et al. (27) reported reduction in caspase-3 expression
suggesting antiapoptotic effects for Ali. On the other hand, administration of Ali at high doses
(50 and 100 mg/kg) protects against the ISO-induced myocardial damage (30).
Fig. 5. (Continued)
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This damaging effect for a low dose of Ali on ISO-induced myocardial injury could be
explained by blocking of the cardiac non-circulatory RAS. In support with this hypothesis, in
this study, we found no change in PRA for rats treated with both ISO and Ali, indicating that
low dose of Ali did not attenuate the ISO-induced elevation in PRA. De Mello et al. (10)
demonstrated that low dose of Ali (5 and 3 mg/kg) signiﬁcantly reduced the myocardial
content of Ang II without affecting PRA suggesting that low dose of Ali mainly blocks
cardiac not circulatory RAS. Also, Khan et al. (30) demonstrated that Ali at doses of 50 and
100 mg/kg blocked both the cardiac and the circulatory RAS completely. Moreover, previous
studies demonstrated the upregulation of myocardial AT1R in ischemic MI (34, 44, 64) and
ISO-induced MI (31). These ﬁndings suggest that Ang II has more effects on the myocardium
when we block RAS by small doses of Ali. Also, in this study, we can explain the damaging
effects of a low dose of Ali on the myocardium by its hypotensive effect. The massive
decrease of peripheral resistance and vasodilatation leads to diastolic and systolic pressure
decrease, despite positive inotropic and chronotropic effects on the heart. In consistence with
this hypothesis, in this study, we reported hypotension in the Ali groups at different times
compared to ISO and NC groups. Also, Leenen et al. (33) demonstrated that the increased
activity of the circulatory RAS appears to blunt the hypotensive effects of ISO. Also, it has
been shown that ISO leads to the development of cardiac hypertrophy without increased
blood pressure as a consequence of increased heart work (28, 43).
Moreover, in this study, the ISO-MI group showed signiﬁcant increase in the duration of
QRS complex, QT interval and ST segment elevation, and increase in HR. These ECG
ﬁndings indicate the development of MI. These ECG ﬁndings of ISO-MI are in agreement
with the previous studies (58, 63). Increased oxidative stress causes loss of cell membrane
function leading to elevation of ST segment, conduction disturbances, and tachycardia (45).
Furthermore, it has been demonstrated that an increase in HR is responsible for the increased
oxygen consumption leading to accelerated myocardial necrosis (67). Also, the QT interval
represents the period of electrical systole of the heart which is determined by inward Na+ and
Ca+2 currents and outward K+ and Cl− currents (29) and is a method for determining the
functional integrity of the myocardium (58). The QT interval prolongation may be related to
cardiac vagal dysfunction and represents cardiac toxic potential, such as indication of
arrhythmias, cardiac dysfunction, and sudden cardiac collapse (40). Changes in cardiac
enzymes, cardiac morphology, and ECG suggest development of full picture of MI in
ISO-induced toxicity. Interestingly, Ali did not cause any improvement in these ECG
variables. Moreover, Ali caused signiﬁcant increase in HR and reduction in duration of
T-wave and makes it tall and peaked, which may be a reﬂection of hyperkalemia induced by
Ali treatment.
Mitochondria represent major sites for generation of ROS as a by-product of oxidative
phosphorylation. Mitochondrial proteins, lipids, and DNA are believed to be primary targets
of oxidative damage during stress (1), thus creating a mitochondrial free radical “vicious
cycle” of injury. Dai et al. (7) provided direct evidence that ampliﬁcation of ROS within
mitochondria is a key mediator of Ang II-induced cardiac hypertrophy and failure. Several
studies have postulated that Ang II may promote the ROS generation in mitochondria through
the ROS-induced ROS release mechanism (3, 9, 69). When, Ang II binds to Ang II type 1
receptor, it activates NADPH oxidase through a protein kinase C (PKC)-dependent manner to
increase ROS production (13). This NAD(P)H oxidase-derived ROS may serve as a trigger to
induce mitoKATP channel opening and mitochondrial permeability transition pore formation,
depolarize mitochondrial membrane potential (ΔψM), and lead to the mitochondrial ROS
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burst (68). Previous studies demonstrated that mice overexpressing CAT targeted to
mitochondria have shown to be resistant to cardiac hypertrophy, ﬁbrosis, and mitochondrial
damage induced by Ang II. Therefore, mitochondria-targeted antioxidants have been
suggested as promising agents for prevention and treatment of hypertensive cardiomyopathy
(7, 8).
The oxidative stress plays an important role in the detrimental effects caused by ISO. In
this study, we demonstrated signiﬁcant elevation in MDA levels in myocardium, which was
associated with signiﬁcant reduction in the anti-oxidant activity of CAT and GSH con-
centrations in the heart tissues. Lipid peroxidation (LPO) product MDA is the result of
oxidation of polyunsaturated fatty acids in the cell membranes, which may cause a decrease
in membrane ﬂuidity and its disruption and impairment of its function (49). The reduction in
the antioxidants, GSH and CAT, could be explained by their excessive utilization during the
burst of ROS production, in protecting SH group containing proteins from LPO (20). These
antioxidants limit the toxicity associated with free radicals and expected to be consumed by
enhanced radical reactions (57). Also, the present results show that low dose of Ali treatment
caused a signiﬁcant increase in MDA levels suggesting the oxidant effects of Ali and
explained the damaging effects of Ali on myocardium partially on basis of enhanced
oxidative stress. We hypothesized that upregulation of AT1R and elevated circulatory RAS
(by low dose of Ali) in ISO-MI increases the production of ROS through NADPH oxidase-
dependent pathway (2, 4, 5) which is activated by AT1R. In support of this hypothesis, Khan
et al. (30) found that 50 and 100 mg/kg doses cause signiﬁcant attenuation of the enhanced
expression of caspase-3 and oxidative stress with more pronounced effect for 100 mg/kg.
In this study, we investigated the expression of Nrf2/HO-1 pathways in ISO-MI and the
impact of renin inhibition on this pathway. Santos et al. (51) reported that a high dose of ISO
can induce ROS production, which activates diverse signaling pathways such as redox-
sensitive transcription factors. Nrf2 is a redox-sensitive transcription factor, which regulates
the induction of phase 2 detoxifying and antioxidant genes (56). Li et al. (36, 37)
demonstrated that Nrf2 is a negative regulator of oxidative stress in cardiomyocytes and
observed that Ang II-activated Nrf2 in the heart and Nrf2 deﬁciency exaggerated Ang II-
induced cardiac hypertrophy. They concluded that increased Nrf2 activity in the myocardium
is secondary to the Ang II-induced oxidative stress because a robust increase in ROS
formation appeared prior to Nrf2 activation in Ang II-stimulated cardiomyocytes in vitro.
Additionally, Nrf2 overexpression suppressed basal ROS formation and blocked Ang II-
induced ROS production in cultured cardiomyocytes, whereas Nrf2 knockdown dramatically
enhanced the basal ROS formation without further increases in Ang II-stimulated ROS
production. Nguyen et al. (42) demonstrated that overexpression of Nrf2 eliminates reactive
oxidants, whereas impaired Nrf2 activity showed the opposite effects. In this study, the
ISO-MI group showed a signiﬁcant increase in Nrf2 expression due to the presence of ROS,
which in turn activates Nrf2. In consistence with this hypothesis, previous studies demon-
strated that mitochondria-derived ROS induce the activation of Nrf2 (35, 53). Also, Li et al.
(35) demonstrated a signiﬁcant increase in Keap1 expression in ISO-treated rats, which
indicates that Nrf2 was rather associated with Keap1, and thus with less translocation of Nrf2
in the nucleus to activate antioxidant gene expression. Under oxidative stress or other
potentially damaging stimuli, Nrf2 dissociates from Keap1 and translocates into the nucleus,
where it binds to the antioxidant response element sequences, leading to the transcriptional
activation of phase II enzymes/antioxidant genes, including HO-1, NQO1, GST, GCL, etc. In
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this study, we demonstrated a signiﬁcant increase in Nrf2 in ISO-MI group compared to NC
group suggesting enhanced expression of Nrf2 in ISO to overcome the oxidative stress in
ISO-MI. Nrf2-mediated antioxidant and phase II enzymes may contribute to cellular
protection against oxidative stress and to potentiate antioxidant defense capacity in cells.
Unfortunately, we found that low dose of Ali caused signiﬁcant attenuation in Nrf2
expression suggesting attenuation of Nrf2 (endogenous protective mechanism against
oxidative stress damage) by excessive ROS, which enhance the myocardial damage as
laboratory and histopathogical examinations reported.
HO-1 is a cytoprotective enzyme that is induced by stress and participates in the
homeostatic control of cardiovascular functions, including the regulation of blood pressure
and the prevention of cardiac ischemic injury (60). Previous studies demonstrated acute HO-1
upregulation in response to ischemic injury in several organs, including the heart (17, 32, 39,
66). Also, previous studies demonstrated that pharmacological activation of HO-1 amelio-
rates post-infarction myocardial remodeling (6) and hepatic ischemic injury (15) and
modulate renal hemodynamics and renal excretory function in renal ischemia (16). In this
study, we found that ISO caused a signiﬁcant increase in the expression of HO-1 and
treatment with Ali at low dose caused minimal reduction in HO-1 suggesting that DRI at low
dose makes more stress on myocardial cells.
Also, in this study, we demonstrated increased apoptosis in the myocardium in the
form of low expression of Bcl2. Although Ali caused signiﬁcant deterioration in myocar-
dial functions and morphology, it caused a signiﬁcant increase in the anti-apoptotic protein
Bcl2. In consistence with these ﬁndings, Jia et al. (27) reported that Ali ameliorated the
cardiomyocytic apoptosis (caspase-3), attenuated the sympathetic nerve innervations
(tyrosine hydroxylase, an GAP43 protein expression) and sprouting and reduced the
vulnerability of ventricular arrhythmias after ischemic MI. Also, Khan et al. (30) demon-
strated that Ali at high dose (50 and 100 mg/kg) signiﬁcantly attenuated the signiﬁcant
increase in caspase-3 expression induced by ISO. Enalapril (10 mg/kg/day), valsartan
(10 mg/kg/day), and carvedilol (beta adrenergic blocker 20 mg/kg/day) (by the same
regime of Ali) have similar effects as Ali on cardiomyocytic apoptosis, sympathetic nerve
innervations, and vulnerability of ventricular arrhythmias after MI. Westermann et al. (61)
showed that Ali treatment for 10 days in ischemic MI (10 and 50 mg/kg) did not affect
systemic blood pressure and improved systolic and diastolic LV function, LV dilatation,
cardiac hypertrophy, and lung weights. This was associated with a normalization of the
mitogen-activated protein kinase P38 and extracellular signal-regulated kinases 1/2, AKT,
and the apoptotic markers Bax and Bcl2 (all measured by Western blots), as well as the
number of terminal deoxynucleotidyl transferase dUTP nick end labeling-positive cells in
histology. LV dilatation, as well as the associated upregulation of gene expression (mRNA
abundance) and activity (by zymography) of the cardiac metalloproteinase 9 in the placebo
group after MI, was also attenuated in the Ali-treated group.
We concluded that early inhibition of RAS by Ali at low dose in ISO-MI enhanced the ISO-
induced deteriorations in myocardial functions and morphology caused by ISO in rats. This
might be due to enhanced oxidative stress and apoptosis and downregulation of Nrf2 and HO-1.
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